Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years on.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18410430.
- Also identified by DOI 10.1111/j.1464-410X.2008.07670.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the last 3 years there has been a dramatic increase in the treatment options for patients with metastatic renal cancer. In addition to the cytokines interferon and interleukin 2, recently approved agents include sorafenib, sunitinib, temsirolimus and bevacizumab. A plethora of agents that are likely to have clinical activity are currently in the development 'pipeline'. This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions.
Medical subject headings
- Antineoplastic Agents
- Kidney Neoplasms
- Protein-Tyrosine Kinases